Subscribe to Newsletter
Diagnostics Liquid biopsy, Point of care testing, Microbiology and immunology, Technology and innovation

A Mouthwatering Malaria Test

Malaria claims over 435,000 lives around the globe each year. In our fight to eradicate the disease, early detection of subclinical and asymptomatic infection (and of those who carry the parasite without falling ill) is vital. However, current blood-based tests are invasive, require administration by clinicians, and often cause patients stress. Now, the world’s first saliva-based rapid diagnostic test (RDT) for malaria – backed by a US$1,199,161 (¥138,269,665) grant from Japan’s Global Health Innovative Technology (GHIT) – seeks to offer a simpler, less invasive alternative (1).

We have a minimally invasive saliva-based test that is easy to use and doesn’t have to be administered by a healthcare professional.

A recent report from the World Health Organization’s Strategic Advisory Group on malaria eradication called for more research and the development of innovative diagnostic tools to replace existing blood tests (2). Rhoel Dinglasan and his team at the University of Florida have answered the call by laying the groundwork for a new saliva test called SALVA!. “We set out to discover and identify protein biomarkers specific to Plasmodium falciparum – or the different phases of the parasite in the human body – in fluids other than blood,” says Dinglasan. Their discovery? A new protein biomarker, PSSP17, that is present in saliva and identifies asymptomatic infected individuals who are likely to progress to malaria within a week.

The testing device is designed to allow healthcare professionals, teachers, and parents to carry out the procedure by taking a small saliva sample – no specialist training is required. Thanks to GHIT’s funding, the next step will be to produce 2,000 SALVA! kits, each containing high-affinity recombinant humanized monoclonal antibodies to detect PSSP17 on a lateral flow test. The devices are then set to be tested in either the Democratic Republic of Congo or Uganda in 2020.

“Once launched, we anticipate the tests will be used globally, but specifically in all endemic areas,” explains Dinglasan. “Mass screening for carrier detection will be the first step in the regional elimination process, but detecting early-stage asymptomatic acute disease – in addition to symptomatic acute disease – will require global roll-out.” The test’s accessibility is a particularly enticing goal. “RDTs are crucial in curtailing malaria and, in this case, we have a minimally invasive saliva-based test that is easy to use and doesn’t have to be administered by a healthcare professional. We hope this early detection can finally make the eradication of malaria a reality.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Erada Technology Alliance, “GHIT Fund Grants £1m+ to Pioneers Behind Saliva-based Diagnostic Tool in Bid to Rid World of Malaria”. Available at: Accessed October 30, 2019.
  2. WHO Strategic Advisory Group on Malaria Eradication, “Malaria eradication: benefits, future scenarios and feasibility” (2019). Available at: Accessed October 30, 2019.
About the Author
Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

The Future of Noninvasive Multi-Cancer Screening

| Contributed by Horizon Discovery

Investigating cell-free DNA in liquid biopsy

| Contributed by Cytiva

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine